The historical rank and industry rank for Neuland Laboratories's Gross Margin % or its related term are showing as below:
NSE:NEULANDLAB'
s Gross Margin % Range Over the Past 10 Years
Min: 32.77 Med: 40.55 Max: 53.18
Current: 53.18
During the past 13 years, the highestGross Margin % of Neuland Laboratories was 53.18%. The lowest was 32.77%. And the median was 40.55%.
NSE:NEULANDLAB's Gross Margin % is ranked better than 58.1% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs NSE:NEULANDLAB: 53.18
Neuland Laboratories had a gross margin of 58.65% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Neuland Laboratories was 6.40% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Neuland Laboratories had a gross margin of 58.65% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Neuland Laboratories Gross Margin % Related Terms
Neuland Laboratories Gross Margin % Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Neuland Laboratories (NSE:NEULANDLAB) has a Gross Margin % of 58.65% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Neuland Laboratories and its competitors. This is 45% above median its historical median of 40.55. Over the past decade, Neuland Laboratories' Gross Margin % has ranged from 32.77 to 53.18. According to the industry distribution chart, Neuland Laboratories ranks #393 out of 938 companies in the Drug Manufacturers industry, placing it in the top 41.9%.
Is Neuland Laboratories' Gross Margin % too high?
Neuland Laboratories' current Gross Margin % of 58.65% is 45% above median its 10-year median of 40.55. Over the past 10 years, this metric has ranged from a low of 32.77 to a high of 53.18. The Drug Manufacturers industry median Gross Margin % is 48.44. Neuland Laboratories' value of 58.65% is 21.1% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #393 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #393 out of 938 companies for Gross Margin %. This puts Neuland Laboratories in the upper half of its industry. The industry median Gross Margin % is 48.44. Neuland Laboratories' value of 58.65% is 21.1% above this benchmark. Historically, Neuland Laboratories' own Gross Margin % has ranged from 32.77 to 53.18 over the past decade. While the company's 10-year median is 40.55 vs. the industry median of 48.44, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current Gross Margin % of 58.65% is 21.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Gross Margin % is 58.65%, which is 45% above median its own 10-year median of 40.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹16,469.67, compared to a current price of ₹17,961.00 — trading 9.1% above its estimated fair value. The current Gross Margin % is 58.65%, which is 45% above median its 10-year median of 40.55 and 21.1% above the Drug Manufacturers industry median of 48.44. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Gross Margin % is 58.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹17,961.00 is trading 9.1% above its estimated GF Value™ of ₹16,469.67.
GuruFocus considers Neuland Laboratories to be Fairly Valued.
Key valuation signals for NSE:NEULANDLAB:
Gross Margin %: 58.65% (45% above median its 10-year median of 40.55)
GF Value™: ₹16,469.67 vs. price of ₹17,961.00 (9.1% above fair value)
Industry Position: 21.1% above the Drug Manufacturers median (#393 of 938)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
